SSGJ-707 in Advanced Non-Small Cell Lung Cancer

Inclusion criteria

• Willing to participate in the study voluntarily, agree to comply with and complete all study procedures, and sign the Informed Consent Form (ICF).
• At least 18 years of age at the time of signing the ICF, regardless of gender.
• Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or 1.
• Life expectancy of at least 12 weeks.
• Histologically or cytologically confirmed locally advanced (Stage IIIB/IIIC) or metastatic (Stage IV) non-small cell lung cancer (NSCLC).
• No prior systemic anti-tumor treatment for locally advanced or metastatic NSCLC.
• At least one measurable tumor lesion as a target lesion according to RECIST v1.1 criteria.

Exclusion criteria

• Presence of small cell carcinoma components in histological pathology.
• Presence of EGFR-sensitive mutations or ALK fusion-positive NSCLC.
• Known BRAF V600E mutation, MET exon 14 skipping mutation, NTRK fusion, RET fusion, or ROS1 fusion-positive NSCLC.
• Presence of brainstem, leptomeningeal, spinal cord metastasis or compression.
• Unresolved toxicity from prior anti-tumor treatment, defined as toxicity not returning to NCI CTCAE Version 5.0 Grade 0 or 1.
• History of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation.
• History of immunodeficiency; positive for HIV antibodies;
• Known active tuberculosis (TB);
• Known history of severe allergy to any component of the investigational drug, or history of severe allergic reactions to chimeric or humanized antibodies.
• Pregnant or breastfeeding women.

The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.